Postcoital bioavailability and antiviral activity of 0.5% PRO 2000 gel: implications for future microbicide clinical trials - Wikidata - wikimedia - TriplyDB

Postcoital bioavailability and antiviral activity of 0.5% PRO 2000 gel: implications for future microbicide clinical trials

Postcoital bioavailability and antiviral activity of 0.5% PRO 2000 gel: implications for future microbicide clinical trials

http://www.wikidata.org/entity/Q28749211

about

sameAs

Advances in HIV microbicide development Microbicides: topical prevention against HIV SPL7013 Gel (VivaGel®) retains potent HIV-1 and HSV-2 inhibitory activity following vaginal administration in humans Clinical parameters essential to methodology and interpretation of mucosal responses A randomized trial to assess anti-HIV activity in female genital tract secretions and soluble mucosal immunity following application of 1% tenofovir gel.Surfactant protein D inhibits HIV-1 infection of target cells via interference with gp120-CD4 interaction and modulates pro-inflammatory cytokine production.In vitro and in vivo evaluation of two carrageenan-based formulations to prevent HPV acquisition.Performance of swabs, lavage, and diluents to quantify biomarkers of female genital tract soluble mucosal mediators Bridging the gap between preclinical and clinical microbicide trials: blind evaluation of candidate gels in murine models of efficacy and safety.PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase 3, randomised, double-blind, parallel-group trial Amyloid-binding small molecules efficiently block SEVI (semen-derived enhancer of virus infection)- and semen-mediated enhancement of HIV-1 infection Enhancement of HIV-1 infectivity by simple, self-assembling modular peptides Female genital tract secretions and semen impact the development of microbicides for the prevention of HIV and other sexually transmitted infections.Topical microbicides to prevent the transmission of HIV: formulation gaps and challenges Topical prophylaxis for HIV prevention in women: becoming a reality.Semen enhances HIV infectivity and impairs the antiviral efficacy of microbicides.In vitro anti-HIV-1 activity in cervicovaginal secretions from pregnant and nonpregnant women.UC781 microbicide gel retains anti-HIV activity in cervicovaginal lavage fluids collected following twice-daily vaginal application Factors Important to the Prioritization and Development of Successful Topical Microbicides for HIV-1 A perspective on progress and gaps in HIV prevention science Impact of Sex on the Pharmacokinetics and Pharmacodynamics of 1% Tenofovir Gel Loss of Innate Host Defense Following Unprotected Vaginal Sex Griffithsin protects mice from genital herpes by preventing cell-to-cell spread Efficacy of HIV antiviral polyanionic carbosilane dendrimer G2-S16 in the presence of semen HIV transmission: time for translational studies to bridge the gap.Intravaginal ring eluting tenofovir disoproxil fumarate completely protects macaques from multiple vaginal simian-HIV challenges.Novel preclinical models of topical PrEP pharmacodynamics provide rationale for combination of drugs with complementary properties First-in-Human Trial of MIV-150 and Zinc Acetate Coformulated in a Carrageenan Gel: Safety, Pharmacokinetics, Acceptability, Adherence, and Pharmacodynamics.Evaluation of PD 404,182 as an anti-HIV and anti-herpes simplex virus microbicide.From the laboratory to clinical trials and back again: lessons learned from HIV prevention trials.Herpes simplex virus 2 infection: molecular association with HIV and novel microbicides to prevent disease.'HIV has a woman's face': vaginal microbicides and a case of ambiguous failure.Carrageenan-based gel retains limited anti-HIV-1 activity 8-24 hours after vaginal application by HIV-infected Thai women enrolled in a phase I safety trial.

P2860

Q26852858-3DB3005D-34AF-4887-87AD-A9446AC1A09B Q26999403-EE493B95-0377-4F85-AF75-C91317767A6A Q28740364-547D9E1C-DBD2-4D57-8AFE-0848B84653B7 Q30398452-3387415F-F3BB-4D54-BE30-82FBFA3E7F6E Q33808638-6775E4EB-82D6-42DA-80E3-474BC7DAB116 Q33921367-AF98A939-BFF5-4101-AF47-FBBBD0C3D7B2 Q33978803-A2AB6F1A-BBD9-4804-976C-3849B221382E Q33999185-71360F37-78C2-48AB-9BDD-6B5FCF3F0A59 Q34078011-87C8C0FC-7B15-44B5-8BCD-C0C5B7F1B435 Q34138687-D7E0F8BA-5D20-45F2-81CD-40748113E0D9 Q34285096-A0856AE3-31AF-45A2-A602-8959CD17BB2D Q34594749-E0E6DFA4-BCEE-412D-9F84-EAC0E7CE7AE7 Q34680240-0756CA1A-3E7F-4503-967F-6073401583A4 Q35009798-FFCA461B-CF30-46E6-BDFB-65071F5CFF36 Q35031133-2C808ACB-3115-41DD-BFB6-5DD448381D66 Q35213456-A8F1919F-E704-4E00-9E8F-40F492567808 Q36059879-60B73A54-BE06-4666-B503-0DA5E7A9C3F0 Q36086344-420ACD89-E665-40EE-9B29-B1EC3156FA53 Q36111516-302B8835-B77F-41A8-BF64-1D5A56E6F35C Q36358897-4F29573A-F17D-474A-8C50-E1DCC540EA02 Q36446138-3505F745-1F76-418D-9308-1A61CD19C5E2 Q36562836-DCF7A119-741F-4230-B858-B9B2CB5F78EA Q36827173-9FA66495-793D-4770-A7E9-F98672CF5B8D Q36967950-75A35F37-BC5B-465D-81A9-20C584639542 Q37156924-E4C9325D-DCB3-4083-9BCC-184051BCB842 Q37218578-4E562744-D872-4ACE-9CF5-8217107B5E40 Q37308347-98F57BB2-A5C4-43FD-B74F-3B2098FF8641 Q37520083-E690675D-9101-4702-BB28-6AEB6EDB3C26 Q37544670-0AAEA443-A624-4BFC-A10F-0A03867D7244 Q38067443-16D49E14-15BE-428C-A27B-32EE0D1D1EA7 Q38248209-5470545A-D207-4E06-B143-8FEF94A4DAB9 Q40964720-3BB1EF11-8E32-49FD-AC7F-89AD2C3D45E9 Q41313440-77A1682C-E953-4C1D-8FD5-611B79384E36

P2860

Postcoital bioavailability and antiviral activity of 0.5% PRO 2000 gel: implications for future microbicide clinical trials

http://www.wikidata.org/entity/Q28749211

description

2010 nî lūn-bûn

@nan

2010 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Postcoital bioavailability and ...... re microbicide clinical trials

@ast

Postcoital bioavailability and ...... re microbicide clinical trials

@en

Postcoital bioavailability and ...... re microbicide clinical trials

@nl

type

label

Postcoital bioavailability and ...... re microbicide clinical trials

@ast

Postcoital bioavailability and ...... re microbicide clinical trials

@en

Postcoital bioavailability and ...... re microbicide clinical trials

@nl

prefLabel

Postcoital bioavailability and ...... re microbicide clinical trials

@ast

Postcoital bioavailability and ...... re microbicide clinical trials

@en

Postcoital bioavailability and ...... re microbicide clinical trials

@nl

P1433

Q28749211-44A8195B-4A9C-4E12-9813-A564D823470B

P1476

Q28749211-56067BD4-848C-4B83-9BEB-20329558D17A

P2093

Q28749211-152B3AAC-A155-440E-BB62-145502950130

Q28749211-2C444610-45B8-49B8-9074-3C35FB4F837B

Q28749211-33FB8CEF-96E2-49C4-92FE-F1C94DCF92D4

Q28749211-387C83DC-45BD-450E-BD9B-43CBDAD9F6FB

Q28749211-3EEED092-0867-4024-B060-698078300824

Q28749211-590B4BEC-018D-4A80-AAB2-2598358DF5EE

Q28749211-72871F3E-4C7A-4BF6-AE8B-DF1B36B99E84

Q28749211-88816831-38A2-48C3-ACD2-C15F4673DDE4

Q28749211-92ADAFE2-6D1F-49D7-A6F7-8E225DEF517C

Q28749211-B78CAB3B-1FD9-4DA5-85EE-F50712BE1E05

P2860

Q28749211-007A62FA-9D7A-4A26-B141-5E23AEE29866

Q28749211-069C6A13-B575-45F4-B296-98CA8B31EB86

Q28749211-12823C44-1AD5-45E3-B950-BDB3DF5580D7

Q28749211-2CC9A477-DE75-4DE1-9AFE-399E81A3382E

Q28749211-30F4C51D-AFC5-4313-A5B8-7BA26C3D8574

Q28749211-41F679A4-22E2-4B10-A1E9-47EE96182F8F

Q28749211-4DAADE69-832E-4A64-8256-55EAC15E2EFE

Q28749211-4E4A416D-DD02-4F3E-931A-B0F29370E1DA

Q28749211-542F82A2-C6A2-48EF-A94B-95D4F66216B2

Q28749211-631B1193-7A6B-41EA-A5C0-A74D81285FAF

P304

Q28749211-AD8687A5-D69E-41C0-95A2-0AA2BCC507F6

P31

Q28749211-A91C63BB-EE60-40E5-8B96-497A2517940D

P3181

Q28749211-A32B23C8-789D-45F4-96F5-F536E8A916FE

P356

Q28749211-3C7608D1-46F0-401E-ABFE-FDD89A4A3894

P407

Q28749211-A8C065C8-AE51-47BA-BE76-90AB90125E96

P433

Q28749211-5C36D283-BA15-498F-840B-F4B5E34AAEE9

P478

Q28749211-E2947CAE-E297-4A71-8D2D-81680F6C2CAE

P50

Q28749211-CFF734B3-9C05-4A41-A9BB-D40CCCB8CB5A

P577

Q28749211-C6968474-A487-4FFB-88FE-A0910B3C2797

P5875

Q28749211-FB3E2960-B29F-4EDD-AE46-5DEFBD5F59C8

P698

Q28749211-796FEF11-098C-4580-BA87-2991CB535DDB

P932

Q28749211-C3548714-42EE-4E61-A1EB-192802710D12

P3181

P356

JOURNAL.PONE.0008781

P1433

P1476

Postcoital bioavailability and ...... re microbicide clinical trials

@en

P2093

Albert T Profy

http://www.w3.org/2001/XMLSchema#string

Betsy C Herold

http://www.w3.org/2001/XMLSchema#string

Gail Shust

http://www.w3.org/2001/XMLSchema#string

Julie Petrie

http://www.w3.org/2001/XMLSchema#string

Lydia Soto-Torres

http://www.w3.org/2001/XMLSchema#string

Marla J Keller

http://www.w3.org/2001/XMLSchema#string

N Merna Torres

http://www.w3.org/2001/XMLSchema#string

Pedro M M Mesquita

http://www.w3.org/2001/XMLSchema#string

Rebecca P Madan

http://www.w3.org/2001/XMLSchema#string

Sylvia Cho

http://www.w3.org/2001/XMLSchema#string

P2860

SAVVY vaginal gel (C31G) for prevention of HIV infection: a randomized controlled trial in Nigeria

Genotypic and phenotypic characterization of HIV-1 patients with primary infection

Semen-derived amyloid fibrils drastically enhance HIV infection

Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1.

Cationic polypeptides are required for anti-HIV-1 activity of human vaginal fluid.

Role of seminal plasma in the anti-HIV-1 activity of candidate microbicides.

Disruption of tight junctions by cellulose sulfate facilitates HIV infection: model of microbicide safety

Enhancement of HIV infection by cellulose sulfate.

Candidate topical microbicides bind herpes simplex virus glycoprotein B and prevent viral entry and cell-to-cell spread.

Sulfated carbohydrate compounds prevent microbial adherence by sexually transmitted disease pathogens.

P304

e8781

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1200896

http://www.w3.org/2001/XMLSchema#string

P356

10.1371/JOURNAL.PONE.0008781

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P50

Hillel W. Cohen

P577

2010-01-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

41166505

http://www.w3.org/2001/XMLSchema#string

P698

20107502

http://www.w3.org/2001/XMLSchema#string

P932

2809740

http://www.w3.org/2001/XMLSchema#string